Hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors
Notes: Autoimmune hemophilia ; Autoimmune inhibitors to clotting factors ; Secondary hemophilia ; Lupus anticoagulant (LAC) with hemorrhagic disorder ; Systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder ; Antithromboplastinemia ; Antithromboplastinogenemia ; Hemorrhagic disorder due to intrinsic increase in antithrombin ; Hemorrhagic disorder due to intrinsic increase in anti-VIIIa ; Hemorrhagic disorder due to intrinsic increase in anti-IXa ; Hemorrhagic disorder due to intrinsic increase in anti-XIa ; antiphospholipid antibody, finding without diagnosis (R76.0) ; antiphospholipid antibody syndrome (D68.61) ; antiphospholipid antibody with hypercoagulable state (D68.61) ; lupus anticoagulant (LAC) finding without diagnosis (R76.0) ; lupus anticoagulant (LAC) with hypercoagulable state (D68.62) ; systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0) ; systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.62)